Introduction How Can We Help? Deliverables Key Benefits Related Products FAQs Contact
Are you currently facing the critical challenges of achieving optimal drug-to-ligand ratios, ensuring target affinity is maintained post-conjugation, or designing stable, releasable therapeutic payloads (protein or peptide)? Creative Biolabs' Aptamer-Conjugate Service helps you engineer next-generation Aptamer-Protein/Peptide Conjugates that streamline targeted therapeutic development. We achieve this through our advanced Rational Design and Optimized Conjugation Chemistry Platform, yielding high-affinity conjugates with controlled stability and release kinetics.
Introduction of Aptamer-Protein/Peptide Conjugate Development
Nucleic acid aptamers are single-stranded DNA or RNA oligonucleotides that fold into unique three-dimensional structures, enabling them to bind specific molecular targets with high affinity and selectivity. These molecules are often referred to as "chemical antibodies" but possess superior characteristics critical for next-generation therapeutics, particularly when utilized as targeting moieties in Aptamer-Drug Conjugates (ApDCs).
What Is Our Service?
We rationally design and chemically synthesize nucleic acid aptamers optimized for high-affinity binding to target molecules, then covalently or physically link them to a therapeutic payload to form a highly selective conjugate for targeted delivery.
-
Targeted Cancer Therapy (ApDCs): Developing conjugates that specifically recognize tumor cell surface markers (receptors, antigens) to deliver cytotoxic drugs directly to the cancer site, minimizing systemic toxicity.
-
Precision Diagnostic Probes: Engineering aptamers to detect ultra-small or transient biomarkers (peptides, amino acid clusters) in patient samples, essential for early-stage disease detection.
-
Targeting "Undruggable" Epitopes: Designing ligands against difficult-to-target protein domains or functional sites that are too small or conformationally sensitive for traditional antibody binding.
Why Choose Us?
We specialize in overcoming the limitations inherent in traditional discovery methods like SELEX, translating scientific challenges into predictable therapeutic benefits for our clients:
|
Pain Points
|
Benefit Created by Creative Biolabs
|
|
Random Screening Dependence
|
Predictable Design. Our in silico guided platform replaces random screening, dramatically reducing discovery time and increasing the probability of success for clinical translation.
|
|
Poor In Vivo Performance
|
Enhanced Stability & Penetration. Aptamers are chemically synthesized and inherently more stable than antibodies, offering better tumor tissue penetration due to their small size.
|
|
Inability to Target Small Epitopes
|
Ultra-Precision Molecular Recognition. We leverage our discovery of amino acid clustering—the ability to target minimal, structurally-defined binding sites—to access previously inaccessible targets.
|
Fig.1 Structure of aptamer-protein/peptide conjugate.1
How Creative Biolabs' Aptamer-Protein/Peptide Conjugate Development Can Assist Your Project?
Creative Biolabs provides a clear, rational pathway from target identification to a validated lead conjugate, ensuring specificity, stability, and therapeutic efficacy. Our core capability lies in defining the molecular recognition event at the highest resolution.
Workflow
-
Required Starting Materials
-
Structure of the target protein
-
Defined protein sequence
-
Known functional binding domains/epitopes
-
Structure of the therapeutic payload
-
Epitope Mapping & In Silico Modeling
-
Rational Aptamer Design & Synthesis
-
Biophysical Characterization & Affinity Validation
-
Conjugate Engineering & Linker Optimization
-
Functional & In Vitro Efficacy Testing
Unlock Your Project's Potential - Inquire for Pricing and Availability Today!
Deliverables
Upon completion of the service, Creative Biolabs provides a comprehensive package of tangible and actionable assets:
-
Comprehensive Final Report: A detailed scientific report summarizing all steps, including computational modeling results, synthesis parameters, and biophysical data analysis.
-
Validated Aptamer and Conjugate Samples: the optimized, chemically synthesized lead aptamer sequence and the final Aptamer-Conjugate formulation for follow-on studies.
-
Raw Data and Model Annotations: Complete raw data sets from all experiments.
Key Benefits
Engineered In Vivo Stability.
Unlike biologically derived ligands, our aptamers are chemically manufactured, allowing for the strategic incorporation of modifications that confer superior nuclease resistance and stability, leading to predictable pharmacokinetics in biological systems.
Superior Tumor Penetration.
The small molecular weight of our engineered aptamers provides a substantial advantage over large ADCs by enabling rapid and deep penetration into solid tumor masses, enhancing the efficacy of the delivered payload.
Reduced Immunogenic Risk.
As nucleic acids, Aptamer-Protein/Peptide Conjugates exhibit minimal to no immunogenicity in humans, eliminating the risk of neutralizing antibodies and allowing for repeated dosing necessary for chronic or advanced therapeutic regimens.
Unlock Your Project's Potential - Inquire for Pricing and Availability Today!
Related Products
Frequently Asked Questions
Q1: How does Creative Biolabs ensure the aptamer-conjugate will be stable in the bloodstream for effective delivery?
A: We address in vivo stability through two primary methods: 1) Chemical modifications are integrated during synthesis to prevent nuclease degradation, and 2) We engineer highly stable, customized linker chemistries that protect the payload (protein/peptide) during circulation while ensuring efficient release upon reaching the tumor microenvironment. Contact us to learn more about our proprietary stabilization protocols.
Q2: My target is a small, previously "undruggable" protein domain. Can your service handle this, or are you limited to large surface antigens?
A: Our Rational Design Platform excels at this challenge. We specifically focus on computationally identifying and targeting the minimal functional units—even non-contiguous amino acid clusters—that large antibodies often miss. This capability is ideal for small, challenging, or conformation-sensitive targets.
Q3: How does an Aptamer-Protein/Peptide Conjugate improve upon delivering the protein or peptide alone?
A: Delivering the payload alone often results in off-target toxicity, rapid systemic clearance, or poor accumulation. Our product utilizes the aptamer as a "chemical address label," dramatically increasing the local concentration of the therapeutic payload at the disease site, improving the therapeutic index and dose efficiency compared to non-targeted delivery.
Contact Us
Creative Biolabs stands at the intersection of structural biology, high-end chemistry, and lead-generation efficiency. Our Aptamer-Protein/Peptide Conjugate Development service delivers high-affinity, highly stable ligands built with the clinical endpoint in mind. Take the critical step toward revolutionizing your therapeutic pipeline. Contact our specialized scientific team, which is ready to discuss your project's unique challenges and how our platform can deliver success.
Reference
-
Fadeev, Michael, et al. "Aptamer–protein structures Guide in silico and experimental discovery of aptamer–short peptide recognition complexes or aptamer–amino acid cluster complexes." The Journal of Physical Chemistry B 126.44 (2022): 8931-8939, Distributed under Open Access license CC BY 4.0, without modification. DOI: https://pubs.acs.org/doi/10.1021/acs.jpcb.2c05624.
For Research Use Only.
Related Sections:
